Search Results - Alexander Muik

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era by Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

    Published in Expert Review of Vaccines (2023-12-01)
    Get full text
    Article


  2. 2

    Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary by Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

    Published in Expert Review of Vaccines (2024-12-01)
    Get full text
    Article


  3. 3

    SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines by Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci

    Published in Frontiers in Immunology (2023-05-01)
    Get full text
    Article


  4. 4

    Corrigendum: SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines by Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci

    Published in Frontiers in Immunology (2023-06-01)
    Get full text
    Article


  5. 5

    The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines by Gary McLean, Jeremy Kamil, Benhur Lee, Penny Moore, Thomas F. Schulz, Alexander Muik, Ugur Sahin, Özlem Türeci, Shanti Pather

    Published in mBio (2022-04-01)
    Get full text
    Article


  6. 6

    Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy by Catherine Dold, Carles Rodriguez Urbiola, Guido Wollmann, Lisa Egerer, Alexander Muik, Lydia Bellmann, Heidelinde Fiegl, Christian Marth, Janine Kimpel, Dorothee von Laer

    Published in Molecular Therapy: Oncolytics (2016-01-01)
    Get full text
    Article


  7. 7

    Toxicological Assessments of a Pandemic COVID-19 Vaccine—Demonstrating the Suitability of a Platform Approach for mRNA Vaccines by Cynthia M. Rohde, Claudia Lindemann, Michael Giovanelli, Rani S. Sellers, Jan Diekmann, Shambhunath Choudhary, Lila Ramaiah, Annette B. Vogel, Yana Chervona, Alexander Muik, Ugur Sahin

    Published in Vaccines (2023-02-01)
    Get full text
    Article


  8. 8

    786 Dose selection for DuoBody®-PD-L1×4-1BB (GEN1046) using a semimechanistic pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data by Manish Gupta, Maria Jure-Kunkel, Alexander Muik, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Ulf Forssmann, Marc Presler, Eleni Lagkadinou, Gaurav Bajaj, Fereshteh Nazari, Craig Thalhauser

    Published in Journal for ImmunoTherapy of Cancer (2021-11-01)
    Article


  9. 9

    1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody®-CD40x4–1BB), exhibits in vivo antitumor activity and peripheral immune modulation by Karsten Pilones, Maria Jure-Kunkel, Homer Adams, Alexander Muik, Tahamtan Ahmadi, Ugur Sahin, Oezlem Tuereci, Kristina Nuermberger, Angelica Sette, Monique Luijten, Maren Köhne, Jasja Wolthoorn, Sina Fellermeier-Kopf

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  10. 10

    Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1 by Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, Maren Bacher, Sebastian Lutz, Maika Grünenthal, Aras Toker, Jessica Grosser, Orkun Ozhelvaci, Olga Blokhina, Svetlana Shpyro, Isabel Vogler, Nadine Salisch, Özlem Türeci, Ugur Sahin

    Published in Cell Reports (2024-08-01)
    Get full text
    Article


  11. 11

    813 Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro by Jordan Blum, Alexander Muik, Isil Altintas, Friederike Gieseke, Aras Toker, Esther Breij, Tahamtan Ahmadi, Ugur Sahin, Kristel Kemper, Oezlem Tuereci, Kristina Nuermberger, Sina Fellermeier-Kopf, Andrea Imle, Anna-Lena Krause, Lidia Daszkiewicz

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  12. 12

    BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants by Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark Cutler, David Cooper, Alexander Muik, Kathrin U. Jansen, Ugur Sahin, Xuping Xie, Philip R. Dormitzer, Pei-Yong Shi

    Published in npj Vaccines (2022-04-01)
    Get full text
    Article


  13. 13

    516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial by Andrés Cervantes, Victor Moreno, Maria Jure-Kunkel, Suresh Ramalingam, Emiliano Calvo, Patricia LoRusso, Brandon Higgs, Suzana Couto, Nora Pencheva, Santiago Ponce Aix, Daniel Cho, Alexander Muik, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Elena Garralda, Ulf Forssmann, Eleni Lagkadinou, José Trigo Pérez, Muhammad Furqan

    Published in Journal for ImmunoTherapy of Cancer (2021-11-01)
    Article


  14. 14

    Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity by Alexander Muik, Bonny Gaby Lui, Jasmin Quandt, Huitian Diao, Yunguan Fu, Maren Bacher, Jessica Gordon, Aras Toker, Jessica Grosser, Orkun Ozhelvaci, Katharina Grikscheit, Sebastian Hoehl, Niko Kohmer, Yaniv Lustig, Gili Regev-Yochay, Sandra Ciesek, Karim Beguir, Asaf Poran, Isabel Vogler, Özlem Türeci, Ugur Sahin

    Published in Cell Reports (2023-08-01)
    Get full text
    Article


  15. 15

    A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade by Işıl Altıntaş, Kristina B. Nürmberger, Andrea Imle, Anna-Lena Krause, Marike M. van Beuge, Aras Toker, Andreea Ioan-Facsinay, Jordan Blum, Alexander Muik, Frank J. Beurskens, Rob N. de Jong, David P. E. Satijn, Friederike Gieseke, Bart-Jan de Kreuk, Maarten van der Kroef, Sina Fellermeier-Kopf, Tahamtan Ahmadi, Özlem Türeci, Esther C. W. Breij, Uğur Şahin

    Published in Scientific Reports (2025-07-01)
    Get full text
    Article


  16. 16

    Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects by Maria Jure-Kunkel, Christina Yu, Nora Pencheva, Mark Fereshteh, Alexander Muik, Aras Toker, Özlem Türeci, Tahamtan Ahmadi, Ugur Sahin, Brandon W Higgs, Jordan M Blum, Saskia M Burm, Vanessa M Spires, Angelica Sette, Sina Fellermeier-Kopf, Andrea Imle, Michela Capello, Kristin Strumane, Theo Plantinga, Craig J Thalhauser, Kristina B Nürmberger, Patricia Garrido Castro, Carol Costa Sa, Bruna de Andrade Pereira

    Published in Journal for ImmunoTherapy of Cancer (2025-04-01)
    Get full text
    Article


  17. 17

    Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine by Kayvon Modjarrad, Ye Che, Wei Chen, Huixian Wu, Carla I. Cadima, Alexander Muik, Mohan S. Maddur, Kristin R. Tompkins, Lyndsey T. Martinez, Hui Cai, Minah Ramos, Sonia Mensah, Brittney Cumbia, Larissa Falcao, Andrew P. McKeen, Jeanne S. Chang, Kimberly F. Fennell, Kevin W. Huynh, Thomas J. McLellan, Parag V. Sahasrabudhe, Wei Chen, Michael Cerswell, Miguel A. Garcia, Shilong Li, Rahul Sharma, Weiqiang Li, Kristianne P. Dizon, Stacy Duarte, Frank Gillett, Rachel Smith, Deanne M. Illenberger, Kari Sweeney Efferen, Annette B. Vogel, Annaliesa S. Anderson, Uğur Şahin, Kena A. Swanson

    Published in npj Vaccines (2024-11-01)
    Get full text
    Article


Search Tools: